[11C]Acetate positron emission tomography in prostate carcinoma. New perspectives in metabolic imaging;Die [11C]Acetat-positronenemissions-tomographie beim prostatakarzinom. Neue perspektiven in der metabolischen bildgebung

Urologe - Ausgabe A

Volumn 41, Issue 6, 2002, Pages 569-576

  Hautzel, H ^a   Muller Mattheis V ^a   Herzog, H ^b   Roden, W ^b   Coenen, H H ^b   Ackermann, R ^a   Muller Gartner H W ^a,b   Krause, B J ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

18FDG; Positron emission computed tomography; Prostate carcinoma; 11C Acetate

Indexed keywords

ACETIC ACID C 11; FLUORODEOXYGLUCOSE F 18; ACETIC ACID DERIVATIVE; AMINO ACID; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL DIFFERENTIATION; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; INTERMETHOD COMPARISON; ISOTOPE LABELING; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATITIS; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; BIOPSY; CASE REPORT; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SCINTISCANNING; TUMOR RECURRENCE;

ACETATES; ADENOCARCINOMA; AMINO ACIDS; BIOPSY; CARBON RADIOISOTOPES; CHOLINE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036878826     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-002-0244-9     Document Type: Article

References (41)

1. Leitlinien zur Therapie von Prostatakarzinomen (1999). Urologe A 38: 630-639
2. DeGrado TR, Baldwin SW, Wang Set al. (2001) Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42: 1805-1814
3. DeGrado TR, Coleman RE et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61: 110-117
4. Effert PJ, Bares R, Handt S et al. (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155: 994-998
5. Garnick MB, Fair WR (1998) Combating prostate cancer. Sci Am 279: 44-53
6. Hara T (2001) 18F-Fluorocholine: a new oncologic PET tracer. J Nucl Med 42: 1815-1817
7. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995
8. Hara T, Kosaka N, Kishi H (2002) Development of (18)F-Fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43: 187-199
9. Heicappell R, Müller-Mattheis V, Reinhardt M et al. (1999) Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36: 582-587
10. Hofer C, Kubler H, Hartung R, Breul J, Avril N (2001) Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 40: 481-487
11. Hofer C, Laubenbacher C, Block T et al. (1999) Fluorine-18-fiuorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36: 31-35
12. Hoh CK, Seltzer MA, Franklin J et al. (1998) Positron emission tomography in urological oncology. J Urol 159: 347-356
13. Kanamaru H, Oyama N, Akino H, Okada K (2000) Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 46: 851-853
14. Kotzerke J, Prang J, Neumaier B et al. (2001) C-11-Azetat Positronen-Emissions-Tomographie für die Diagnostik des Prostatakarzinoms. Nuklearmedizin 40: A32
15. Kotzerke J, Prang J, Neumaier B et al. (2000) Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27: 1415-1419
16. Kotzerke J, Volkmer B, Neumaier B et al. (2002) C-11-Azetat-PET zur Detektion des Lokalrevidivs nach Prostatakarzinom. Abstractband der 40. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin, S 47
17. Kurhanewicz J, Vigneron DB, Hricak H et al. (1996) Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 200: 489-496
18. Langen KJ, Börner AR, Müller-Mattheis V et al. (2001) Uptake of cis-4-[18F] fluoro-L-proline in urologic tumors. J Nucl Med 42: 752-754
19. Liu A, Carlson KE, Katzenellenbogen JA (1992) Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potenzial agents for imaging prostatic cancer by positron emission tomography. J Med Chem 35: 2113-2129
20. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57: 108-111
21. Lowe VJ, Duhaylongsod FG, Patz EF et al. (1997) Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 202: 43S-439
22. Morris MJ, Akhurst T, Osman I et al. (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59: 913-918
23. Nunez R, Macapinlac HA, Yeung HW et al. (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43: 46-55
24. Oyama N, Akino H, Kanamaru H, Okada K (1998) [Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer]. Nippon Rinsho 56: 2052-2055
25. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K (2002) 11C-acetate PET imaging of prostate cancer. J Nucl Med 43: 181-186
26. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, Sadato N, Yonekura Y, Okada K (2001) FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl.Med.Commun. 22: 963-969
27. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, Okada K (1999) The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29: 623-629
28. Price DT, Coleman RE, Liao RP et al. (2002) Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168: 273-280
29. Sanz G, Robles JE, Gimenez M et al. (1999) Positron emission tomography with 18fluorinelabelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84: 1028-1031
30. Seltzer MA, Barbaric Z, Belldegrun A et al. (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162: 1322-1328
31. Seltzer MA, Jahan S, Dahlbom M et al. (2002) 11C-Acetate PET imaging of primary and locally recurrent prostate cancer: Comparison to normal controls. Society of Nuclear Medicine, 49th Annual Meeting: 422
32. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD (1995) Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36; 1595-1601
33. Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19: 61-77
34. Shreve PD, Gross MD (1997) Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 38: 1305-1310
35. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199: 751-756
36. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23: 1409-1415
37. Varagnolo L, Stokkel MP, Mazzi U, Pauwels EK (2000) 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol 27: 103-112
38. Weckesser E, Stief CG, Otto D et al. (2001) Erste Erfahrungen mit C11-Azetat-PET bei Patienten mit Prostatakarzinomen. Nuklearmedizin 40: A32-33
39. Yeh SD, Imbriaco M, Larson SM et al. (1996) Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23: 693-697
40. Yoshimoto M, Waki A, Yonekura Y et al. (2001) Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28: 117-122
41. Yu KK, Hricak H (2000) Imaging prostate cancer. Radiol Clin North Am 38: 59-85